In this episode, join GU cancer experts Scott Tagawa (Weill Cornell Medicine and New York Presbyterian, New York City, NY), Karie Runcie (Columbia University Irving Medical Center, New York City, NY), and Tanya Dorff (City of Hope Comprehensive Cancer Center, Duarte, CA) as they discuss the most important clinical trial data for prostate, bladder, and kidney cancer at the ASCO GU Cancers Symposium 2023.

In prostate cancer, PARP inhibitors were a hot topic of discussion, with data from TALAPRO-2 (NCT03395197) and TRITON3 (NCT02975934) being presented. In bladder cancer, IMvigor130 (NCT02807636) and TROPHY-U-01 (NCT03547973) were two of the key trials, with additional discussions on antibody-drug conjugates (ADCs), nectin-4-targeted therapies, and the use of molecular profiling in clinical practice. Finally, in kidney cancer, there were updates from ZIRCON (NCT03849118), COSMIC-313 (NCT03937219), and CheckMate 9ER (NCT03141177).